Clinical Trials
Orphazyme completes enrollment in phase 3 trial evaluating arimoclomol in amyotrophic lateral sclerosis
Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases announces that it has completed enrollment in its phase...
Packaging & Labelling
CURE Pharmaceutical Secures Patent on Oral Thin Films With Bi-Phasic Release of Natural Ingredients
CURE Pharmaceutical , an innovative drug delivery and development company announced the allowance of U.S, which covers edible thin films with natural active ingredients...
Press Releases
Cryoport and EVERSANA Form Strategic Alliance to Accelerate Regenerative Medicine Supply Chain
Cryoport and EVERSANA have announced a strategic alliance to further create a fully integrated regenerative medicine supply chain solution.
The alliance will be designed to...
Press Releases
Novartis key multiple sclerosis product Gilenya approved in China
"It is exciting news for MS patients in China that Gilenya has received fast approval. The approval of Gilenya and the upcoming regulatory review...
Press Releases
Catalent Biologics Announces Agreement To Provide Additional Production Of Approved Gene Therapy Treatment For Spinal Muscular Atrophy
Catalent Biologics announced a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular...
Press Releases
Huge CPhI P MEC China a direct result of surging manufacturing
Organized by China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE), Informa Markets, and Shanghai Sinoexpo Informa Markets –...
News
TraceLink Partners With Excellis to Provide Local Implementation Services for its Russia Compliance Solution Through One Global Compliance Platform
TraceLink Inc., the world’s largest integrated digital supply network, providing real-time information sharing for better patient outcomes, announced a partnership with Excellis Health Solutions...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read